# Combination Lipid-Lowering Therapy After ACS: Should this be the New Standard of Care?

## TL;DR

This paper reviews whether combining lipid-lowering treatments soon after a heart attack should become the standard care.

## Contribution

It highlights the potential of early combination therapy to improve cholesterol control and reduce heart risks, while addressing treatment gaps.

## Key findings

- Combination therapy helps reach cholesterol goals faster after a heart attack.
- Current guidelines suggest earlier combination therapy but real-world implementation is lacking.
- Personalized care must be balanced with simplified treatment strategies.

## Abstract

To examine whether early combination lipid-lowering therapy after acute coronary syndrome (ACS) should be considered as a standard approach. The review assesses current international guideline recommendations, supporting clinical evidence, and real-world implementation gaps.

Recent European and U.S. guidelines emphasise lower low-density lipoprotein-cholesterol (LDL-C) targets and suggest earlier use of combination therapy. Data from randomised trials, registry-based emulations, and observational cohorts demonstrate that early initiation of high-intensity regimens improves LDL-C goal attainment and may reduce the recurrence of cardiovascular events. However, registry data reveal substantial global undertreatment and limited treatment intensification.

Early combination therapy represents a pragmatic strategy to accelerate LDL-C goal achievement after ACS. While this approach could narrow current treatment gaps, it must be balanced against the trend toward personalised, risk-based lipid management. Future research should address how simplified treatment algorithms can coexist with individualised care frameworks.